CSM-101
Asset
CNS-penetrant small-molecule TRPML1 agonist
- Stage
- Preclinical
- Modality
- Small molecule
- Target
- Autophagy
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
2Gaucher disease
Preclinical, casmatx.com, 7 Oct 2026
Parkinson's disease
Preclinical, casmatx.com, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets2
- Competitors12
- Aging relevance2
Every asset’s record: target, stage, trials and the evidence behind it.